Share chart BioMarin Pharmaceutical
About
BioMarin Pharmaceutical Inc. — американская биотехнологическая компания со штаб-квартирой в Сан-Рафаэле, Калифорния . У него есть офисы и помещения в США , Южной Америке , Азии и Европе . Основным направлением деятельности и исследованиями BioMarin является заместительная терапия ферментами (ФЗТ).
More details| Цена ао | 85.12 |
|---|---|
| P/E | 19.34 |
| P/S | 8.83 |
| P/BV | 4.82 |
| EV/EBITDA | -694.6 |
| EBITDA | -0.0222 |
| Сайт | http://www.biomarin.com |
| Число акций ао | 0.1916 млрд |
| Выручка | 1.704 |
| Див.доход ао | 0 |
| ISIN | US09061G1013 |
| Change price per day: | -1.7204% (86.61) |
|---|---|
| Change price per week: | -8.05% (92.57) |
| Change price per month: | +1.249% (84.07) |
| Change price per 3 month: | +13.4% (75.06) |
| Change price per half year: | -1.3445% (86.28) |
| Change price per year: | -9.91% (94.48) |
| Change price per 3 year: | -4.47% (89.1) |
| Change price per 5 year: | -27.96% (118.16) |
| Change price per year to date: | -11.83% (96.54) |
All parameters ⇨
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
|---|---|---|---|---|---|---|---|---|---|
| 10.05.2024 | 13.05.2024 | BIENAIME JEAN JACQUES Director |
Sale | 81.14 | 1 622 800 | 20000 | 0 | -0.01 | link |
| 10.05.2024 | 13.05.2024 | BIENAIME JEAN JACQUES Director |
Purchase | 63.1 | 1 262 000 | 20000 | 0 | 0.01 | link |
| 09.05.2024 | 13.05.2024 | BIENAIME JEAN JACQUES Director |
Sale | 81.62 | 1 632 400 | 20000 | 0 | -0.01 | link |
| 09.05.2024 | 13.05.2024 | BIENAIME JEAN JACQUES Director |
Purchase | 63.1 | 1 262 000 | 20000 | 0 | 0.01 | link |
| 12.04.2024 | 15.04.2024 | BIENAIME JEAN JACQUES Director |
Sale | 91.26 | 1 825 200 | 20000 | 0 | -0.01 | link |
| 12.04.2024 | 15.04.2024 | BIENAIME JEAN JACQUES Director |
Purchase | 63.1 | 1 262 000 | 20000 | 0 | 0.01 | link |
| 11.04.2024 | 15.04.2024 | BIENAIME JEAN JACQUES Director |
Sale | 90.99 | 1 819 800 | 20000 | 0 | -0.01 | link |
| 11.04.2024 | 15.04.2024 | BIENAIME JEAN JACQUES Director |
Purchase | 63.1 | 1 262 000 | 20000 | 0 | 0.01 | link |
| 10.04.2024 | 12.04.2024 | Burkhart Erin GVP, Chief Accounting Officer |
Sale | 90 | 205 740 | 2286 | 0 | 0 | link |
| 10.01.2024 | 11.01.2024 | BIENAIME JEAN JACQUES Director |
Sale | 96.38 | 963 800 | 10000 | 0 | -0.01 | link |
| 10.01.2024 | 11.01.2024 | BIENAIME JEAN JACQUES Director |
Purchase | 63.1 | 631 000 | 10000 | 0 | 0.01 | link |
| 09.01.2024 | 11.01.2024 | BIENAIME JEAN JACQUES Director |
Sale | 98.19 | 981 900 | 10000 | 0 | -0.01 | link |
| 09.01.2024 | 11.01.2024 | BIENAIME JEAN JACQUES Director |
Purchase | 63.1 | 631 000 | 10000 | 0 | 0.01 | link |
| 13.12.2023 | 14.12.2023 | Davis George Eric EVP, Chief Legal Officer |
Sale | 95.3 | 1 311 710 | 13764 | 0 | -0.01 | link |
| 08.08.2023 | 09.08.2023 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 88.29 | 529 740 | 6000 | 0 | 0 | link |
| 08.08.2023 | 09.08.2023 | Davis George Eric EVP, Chief Legal Officer |
Sale | 89.42 | 983 620 | 11000 | 0 | -0.01 | link |
| 07.08.2023 | 09.08.2023 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 88.1 | 352 400 | 4000 | 0 | 0 | link |
| 10.05.2023 | 11.05.2023 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 94.85 | 2 845 500 | 30000 | 0 | -0.02 | link |
| 10.05.2023 | 11.05.2023 | BIENAIME JEAN JACQUES Chief Executive Officer |
Purchase | 67.81 | 2 034 300 | 30000 | 0 | 0.02 | link |
| 09.05.2023 | 11.05.2023 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 94.93 | 2 847 900 | 30000 | 0 | -0.02 | link |
| 09.05.2023 | 11.05.2023 | BIENAIME JEAN JACQUES Chief Executive Officer |
Purchase | 67.81 | 2 034 300 | 30000 | 0 | 0.02 | link |
| 06.04.2023 | 10.04.2023 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 96.13 | 961 300 | 10000 | 0 | -0.01 | link |
| 06.04.2023 | 10.04.2023 | BIENAIME JEAN JACQUES Chief Executive Officer |
Purchase | 67.81 | 678 100 | 10000 | 0 | 0.01 | link |
| 25.01.2023 | 27.01.2023 | Ajer Jeffrey Robert EVP, Chief Commercial Officer |
Sale | 115.7 | 5 669 300 | 49000 | 0 | -0.03 | link |
| 25.01.2023 | 27.01.2023 | Ajer Jeffrey Robert EVP, Chief Commercial Officer |
Purchase | 67.81 | 3 322 690 | 49000 | 0 | 0.03 | link |
| 14.10.2022 | 18.10.2022 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 89.89 | 359 560 | 4000 | 0 | 0 | link |
| 15.08.2022 | 16.08.2022 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 95.21 | 285 630 | 3000 | 0 | 0 | link |
| 12.08.2022 | 16.08.2022 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 94.75 | 379 000 | 4000 | 0 | 0 | link |
| 11.08.2022 | 12.08.2022 | Ajer Jeffrey Robert EVP, Chief Commercial Officer |
Sale | 95.62 | 286 860 | 3000 | 0 | 0 | link |
| 08.08.2022 | 10.08.2022 | Guyer Charles Greg EVP, Chief Technical Officer |
Sale | 96.56 | 599 155 | 6205 | 0 | 0 | link |
| 08.07.2022 | 11.07.2022 | Davis George Eric EVP, Chief Legal Officer |
Sale | 90 | 665 820 | 7398 | 0 | 0 | link |
| 25.04.2022 | 27.04.2022 | Davis George Eric EVP, Chief Legal Officer |
Purchase | 37.46 | 99 981 | 2669 | 0 | 0 | link |
| 13.04.2022 | 14.04.2022 | Ajer Jeffrey Robert EVP, Chief Commercial Officer |
Sale | 82.47 | 97 315 | 1180 | 0 | 0 | link |
| 14.01.2022 | 19.01.2022 | LAWLIS V BRYAN Director |
Sale | 87.61 | 372 343 | 4250 | 0 | 0 | link |
| 14.01.2022 | 19.01.2022 | LAWLIS V BRYAN Director |
Purchase | 37.46 | 159 205 | 4250 | 0 | 0 | link |
| 13.01.2022 | 14.01.2022 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 87.86 | 439 300 | 5000 | 0 | 0 | link |
| 13.01.2022 | 14.01.2022 | BIENAIME JEAN JACQUES Chief Executive Officer |
Purchase | 37.46 | 187 300 | 5000 | 0 | 0 | link |
| 12.01.2022 | 14.01.2022 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 89 | 445 000 | 5000 | 0 | 0 | link |
| 12.01.2022 | 14.01.2022 | BIENAIME JEAN JACQUES Chief Executive Officer |
Purchase | 37.46 | 187 300 | 5000 | 0 | 0 | link |
| 26.10.2021 | 28.10.2021 | Ajer Jeffrey Robert EVP, Chief Commercial Officer |
Sale | 73.6 | 201 590 | 2739 | 0 | 0 | link |
| 10.05.2021 | 12.05.2021 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 77.29 | 657 970 | 8513 | 0 | 0 | link |
| 10.05.2021 | 12.05.2021 | BIENAIME JEAN JACQUES Chief Executive Officer |
Purchase | 26.49 | 225 509 | 8513 | 0 | 0 | link |
| 07.05.2021 | 11.05.2021 | Mueller Brian EVP, Chief Financial Officer |
Sale | 79.5 | 533 366 | 6709 | 0 | 0 | link |
| 18.03.2021 | 19.03.2021 | Ajer Jeffrey Robert EVP, Chief Commercial Officer |
Sale | 77.99 | 102 011 | 1308 | 0 | 0 | link |
| 29.01.2021 | 01.02.2021 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 82.67 | 688 972 | 8334 | 0 | 0 | link |
| 29.01.2021 | 01.02.2021 | BIENAIME JEAN JACQUES Chief Executive Officer |
Purchase | 26.49 | 220 768 | 8334 | 0 | 0 | link |
| 28.01.2021 | 01.02.2021 | BIENAIME JEAN JACQUES Chief Executive Officer |
Sale | 82.91 | 690 889 | 8333 | 0 | 0 | link |
| 28.01.2021 | 01.02.2021 | BIENAIME JEAN JACQUES Chief Executive Officer |
Purchase | 26.49 | 220 741 | 8333 | 0 | 0 | link |
| Institutions | Volume | Share, % |
|---|---|---|
| PRIMECAP Management Company | 18414374 | 9.76 |
| Vanguard Group Inc | 18050062 | 9.57 |
| Blackrock Inc. | 14681644 | 7.78 |
| Dodge & Cox Inc | 13994063 | 7.42 |
| Capital Research Global Investors | 10774641 | 5.71 |
| State Street Corporation | 6730515 | 3.57 |
| Ameriprise Financial, Inc. | 5419366 | 2.87 |
| Barclays PLC | 5288893 | 2.8 |
| Viking Global Investors, L.P. | 4889454 | 2.59 |
| Avoro Capital Advisors LLC | 4300000 | 2.28 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Evolved U.S. Innovative Healthcare ETF | 1.35 | 27.98 | 2.79 |
| FinEx USA UCITS ETF | 0.03 | 54.54 | |
| VanEck Biotech ETF | 2.72 | 38.53 | 0.43 |
| Invesco Biotechnology & Genome ETF | 5.59 | 37.15 | 0.06 |
| Global X Genomics & Biotechnology ETF | 3.59 | 39.55 | |
| ProShares Ultra Nasdaq Biotechnology | 1.1 | 57.51 | 0.14 |
| Invesco Nasdaq Biotechnology ETF | 1.66 | 0.82 | |
| First Trust Innovation Leaders ETF | 1.73 | ||
| Goldman Sachs Future Health Care Equity ETF | 3.02 | 0.52 | |
| SPDR S&P Midcap 400 ETF Trust | 0.6 | 43.80 | 1.20 |
| SPDR Portfolio S&P 400 Mid Cap ETF | 0.6 | 43.90 | 1.42 |
| iShares Biotechnology ETF | 1.57 | 31.10 | 0.29 |
| SPDR S&P Biotech ETF | 2.69 | 23.57 | 0.14 |
| iShares Core S&P Mid-Cap ETF | 0.59 | 44.04 | 2.93 |
| Direxion Daily S&P Biotech Bull 3x Shares | 2.19 | 32.14 | 0.49 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Brian R. Mueller | CFO & Executive VP | 1.15M | 1974 (50 years) |
| Mr. Jeffrey Robert Ajer | Executive VP & Chief Commercial Officer | 1.18M | 1962 (62 years) |
| Mr. George Eric Davis | Executive VP, Chief Legal Officer, General Counsel & Secretary | 1.23M | 1971 (53 years) |
| Dr. Henry J. Fuchs M.D., Ph.D. | President of Worldwide Research & Development | 1.49M | 1958 (66 years) |
| Ms. Erin Burkhart | Group VP & Chief Accounting Officer | N/A | |
| Ms. Marni Kottle | Executive VP & Chief Corporate Affairs Officer | N/A | |
| Mr. Alexander Hardy | President, CEO & Director | N/A | 1969 (55 years) |
| Dr. Ganesh Vedantham Ph.D. | Senior Vice President of Technical Development | N/A | |
| Jonathan Day Ph.D. | Executive Medical Director of Clinical Science | N/A | |
| Dr. Yen Wong Wing | Vice President of Clinical Science | N/A | |
Address: United States, San Rafael, CA , 770 Lindaro Street - open in Google maps, open in Yandex maps
Website: http://www.biomarin.com
Website: http://www.biomarin.com
